| » |
The development of this vaccine is based on auto-immune model inducing selective cytoxicity and reversing the process of AIDS in HIV infected people resulting in reactivation of natural immunity. |
| » |
The vaccine is based on inducing selective cytotoxicity and reversing the process of AIDS in HIV infected people, resulting in reactivation of natural immunity in AIDS patients, devoid of any side effects and recovering back to normal life. |
| » |
TBL has successfully developed the genetically engineered clones and produced the target vaccine. |
| » |
The vaccine so produced has demonstrated the expected and exciting results in selective killing of HIV infected cells which are the target for our vaccine. |
| » |
The vaccine has demonstrated exciting results in selective killing of only the HIV infected cells unlike any other existing drug, the results being validated by the expert scientific committee. |
| » |
Patent applications to cover USA and PCT countries have already been filed. We are preparing to file additional patents soon. |
| » |
Pre-clinical studies are expected to be completed by the end of Q1, 2010-11. |
| » |
TBL plans to out-license this drug soon after completion of pre-clinical trials. |
